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INTRODUCTION AND OBJECTIVE: The heptapeptide angiotensin-(1-7) is a component of the renin-angiotensin
system, which promotes many beneficial cardiovascular effects, including antithrombotic activity. We have recently
shown that the antithrombotic effect of angiotensin-(1-7) involves receptor Mas-mediated NO-release from
platelets. Here, we describe an orally active formulation based on angiotensin-(1-7) inclusion in cyclodextrin [Ang-
(1-7)- CyD] as an antithrombotic agent. Cyclodextrins are pharmaceutical tools that are used to enhance drug
stability, absorption across biological barriers and gastric protection.
METHOD: To test the antithrombotic effect of Ang-(1-7)-CyD, thrombus formation was induced in the abdominal
vena cava of spontaneously hypertensive rats that were pretreated either acutely or chronically with Ang-(1-7)-CyD.
Male Mas-knockout and wild-type mice were used to verify the role of the Mas receptor on the effect of Ang-(1-7)-
CyD.
RESULTS: Acute or chronic oral treatment with Ang-(1-7)-CyD promoted an antithrombotic effect (measured by
thrombus weight; all values are, respectively, untreated vs. treated animals) in spontaneously hypertensive rats
(acute: 2.86¡ 0.43 mg vs. 1.14¡ 0.40 mg; chronic: 4.27¡ 1.03 mg vs. 1.39¡ 0.68 mg). This effect was abolished in
Mas-knockout mice (thrombus weight in Mas wild-type: 0.76 ¡ 0.10 mg vs. 0.37 ¡ 0.02 mg; thrombus weight in
Mas-knockout: 0.96 ¡ 0.11 mg vs. 0.87 ¡ 0.14 mg). Furthermore, the antithrombotic effect of Ang-(1-7)-CyD was
associated with an increase in the plasma level of Angiotensin-(1-7).
CONCLUSION: These results show for the first time that the oral formulation Ang-(1-7)-CyD has biological activity
and produces a Mas-dependent antithrombotic effect.
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INTRODUCTION
Thrombogenic events such as ischemic stroke, pulmonary
embolism, deep venous thrombosis, mesenteric ischemia,
and acute coronary syndrome are major complications of
some pathological conditions, including hypertension,
atherosclerosis and diabetes mellitus.1 Despite the large
number of therapeutic advances that have led to increas-
ingly effective drug treatments, thrombogenic events still
are a major cause of morbidity and mortality worldwide,2
and significant efforts have been made to identify new anti-
thrombotic therapies.
The renin-angiotensin system (RAS) is the major hormo-
nal system regulator of cardiovascular function; it plays a
pivotal role in the homeostasis of arterial pressure, cardiac
function, hydroelectrolyte balance, and it participates in
hemostasis.3 The vasoactive peptide angiotensin (Ang) II is
the main active member of the RAS; some of the most
important current therapies for cardiovascular pathologies
include blockade of the synthesis and/or activity of Ang II
using angiotensin-converting enzyme (ACE) inhibitors4 or
angiotensin receptor blockers (ARBs).5
Ang-(1-7) is another biologically active component of the
RAS; its actions are often the opposite of those described for
Ang II.6,7 Ang II promotes cell proliferation, vasoconstric-
tion and pro-thrombotic activity, whereas Ang-(1-7) has
antiproliferative, vasodilator and antithrombotic actions,
suggesting that it has great potential to treat cardiovascular
diseases.8,9 The intrinsic antithrombotic effects of ACE
inhibitors and ARBs may be mediated by Ang-(1-7)10
because these drugs increase the plasma level of
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Ang-(1-7).11 We recently showed that the antithrombotic
effect of Ang-(1-7) depends on Mas,12 the known receptor
for Ang-(1-7). 13 Furthermore, we demonstrated that Mas is
present on platelets and that the interaction between Ang-
(1-7) and Mas the only known recepter on these cells
promotes the production of nitric oxide (NO).12
Many protein and peptide drugs cannot be administered
orally because they are degraded by stomach and intestinal
digestive enzymes.14 Cyclodextrins (CyDs) are pharmaceu-
tical tools that are used to design and evaluate drug
formulations that can be used to enhance drug stability,
absorption across biological barriers and gastric protec-
tion.14 These compounds are cyclic oligosaccharides that
consist of six to eight glucopyranose units that form
molecules with polar outer surfaces and an apolar cavity.
Their amphiphilic characteristics make them soluble and
allow the formation of supramolecular inclusion complexes
that are stabilized by non-covalent interactions with a
variety of guest molecules.14 CyDs are neither hydrolyzed
nor absorbed in the stomach or small intestine. However,
the colon microflora break them into small saccharides,
delivering the included molecule to the large intestine,
where it may be absorbed.15 A formulation based on Ang-
(1-7) included in CyD [Ang-(1-7)-CyD] was recently
characterized; however, its biological action has not been
evaluated.15
In the present study, we show for the first time that Ang-
(1-7)-CyD possesses biological activity and promotes an
antithrombotic effect.
METHODS
Animals
The following animals were used: 15-week-old sponta-
neously hypertensive rats (SHRs) that were bred at the
Biological Science Institute (CEBIO, Federal University of
Minas Gerais) and Mas-knockout (Mas-/-) and wild-type
(Mas+/+) male mice on a pure genetic background C57BL/6
(15 weeks old) that were produced at the Max-Delbru¨ck
Center for Molecular Medicine, Berlin and maintained
at the transgenic animal facility of the Laboratory of
Hypertension, Biological Science Institute, Federal
University of Minas Gerais (UFMG). Animals were kept in
temperature-controlled rooms with 12 h/12 h light/dark
cycles and free access to water and food. The animal care
committee from the UFMG, Brazil, approved all experi-
mental protocols.
Thrombus induction in rats
The effects of acute [10 mg/kg, 30 mg/kg or 100 mg/kg of
Ang-(1-7) 5 hours before thrombus induction and chronic
[30 mg/ kg of Ang-(1-7)-CyD once per day for eight weeks]
oral administration of Ang-(1-7)-CyD were tested in SHR.
Thrombus formation was induced in the abdominal vena
cava by ligature, as described previously.10 Twelve hours
before thrombus induction, the SHRs were deprived of food
but had free access to water. For each rat, the abdomen was
opened under ketamine/xylazine anesthesia (100 mg/kg of
ketamine and 10 mg/kg of xylazine), and the vena cava was
carefully separated from the surrounding tissues and
ligated tightly with a cotton thread just below the left renal
vein. The abdomen was then closed with a double layer of
sutures (peritoneum with muscles and skin separately).
After two hours, each animal was reanesthetized, the
abdomen was reopened, and the vena cava was carefully
dissected and inspected for the presence of thrombus. The
thrombus was air-dried at 37 C˚ overnight, and its weight
was measured.
Thrombus induction in mice
To test the role of Mas on the antithrombotic effect of
Ang-(1-7)-CyD, thrombus formation was induced in the
abdominal vena cava of Mas-/- and Mas+/+ mice with a ferric
chloride (FeCl3) solution, as described previously.
12 Mice
were deprived of food but had free access to water twelve
hours before thrombus induction. Acute oral administration
of Ang-(1-7)-CyD [100 mg/kg of Ang-(1-7)] was performed
two hours before starting the surgical procedures. After
anesthesia (ketamine 100 mg/kg, xylazine 10 mg/kg), the
abdomen was opened, and the vena cava was exposed and
carefully ligated with a cotton thread just below the left
renal vein. A filter paper (2 mm6 5 mm) steeped in a 35%
ferric chloride solution was applied below the ligature.
After thirty minutes, the thrombus that formed was care-
fully removed and air-dried at 37 C˚ overnight. The
thrombotic response was assessed by measuring the
thrombus weight.
Figure 1 - Ang-(1-7)-CyD promoted antithrombotic effects in
SHRs. A) Acute treatment with Ang-(1-7)-CyD (five hours before
thrombus induction) inhibited thrombus formation when admi-
nistered in doses of the equivalent of 10 mg/kg or 30 mg/kg of
Ang-(1-7). B) Chronic administration of Ang-(1-7)-CyD [equiva-
lent of 30 mg/kg of Ang-(1-7) per day] over the course of eight
weeks promoted a strong inhibition of thrombus formation in
SHRs. *p,0.05 significantly different from the respective control
group treated with CyD (one-way ANOVA for panel A and
unpaired Student’s t-test for panel B). Each column represents
the mean ¡ SEM from 7-10 experiments.
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Radioimunnoassay
Wild type mice underwent acute oral administration of
Ang-(1-7)-CyD [100 mg/kg of Ang-(1-7)] two hours prior to
blood collection. Blood samples were obtained by decapita-
tion and collected in polypropylene tubes containing 1 mM
p-hydroxymercury benzoate, 30 mM 1, 10-phenanthroline,
1 mM PMSF, 1 mM pepstatin A, and 7.5% EDTA (100 ml/ml
of blood).16 The samples were pooled in groups of four to
improve the sensitivity of the assay. After centrifugation,
plasma samples were frozen and stored at -80 C˚.
The samples were extracted onto a Bond-Elut phenyl-
silica cartridge (Varian, USA). The columns were pre-
activated by sequential washes with 10 ml of 99.9%
acetonitrile/0.1% heptafluorobutyric acid (HFBA) and
10 ml of 0.1% HFBA. Sequential washes with 10 ml of
99.9% acetonitrile/0.1% HFBA, 10 ml of 0.1% HFBA, 3 ml of
0.1% HFBA containing 0.1% bovine serum albumin (BSA),
10 ml of 10% acetonitrile/0.1% HFBA and 3 ml of 0.1 %
HFBA were used to activate the columns. After sample
application, the columns were washed with 20 ml of 0.1%
HFBA and 3 ml of 20% acetonitrile/0.1% HFBA. The
adsorbed peptides were eluted with 3 ml of 99.9%
acetonitrile/0.1% HFBA into polypropylene tubes rinsed
with 0.1% BSA.13 After evaporation, angiotensin peptide
levels were measured by a radioimmunoassay (RIA), as
described previously.17
Statistical analysis
The results are expressed as mean ¡ SEM. Statistical
analyses for SHR thrombus formation after chronic treatment,
mouse thrombus formation, and plasma Ang-(1-7) level
measurements were performed using the unpaired Student’s
t-test. The statistical analysis for SHR thrombus formation
following acute treatment was performed by one-way
ANOVA followed by a Dunnett post-test.
RESULTS
Acute and prolonged treatment with Ang-(1-7)-CyD
promotes an antithrombotic effect in SHR
As shown in Figure 1A, acute treatment with Ang-(1-7)-
CyD, equivalent to 10 mg or 30 mg of Ang-(1-7), promoted a
significant antithrombotic effect in SHRs. The maximal
effect occurred at a dose of 30 mg of Ang-(1-7); this dose
promoted a 60% inhibition of thrombus formation (2.86¡
0.43 mg vs. 1.14 ¡ 0.40 mg, n = 9 and n = 10, respectively;
this and all subsequent comparisons refer to untreated vs.
treated). As observed in other dose-response studies with
other Ang-(1-7) effects,10,12 a higher dose of Ang-(1-7),
equivalent to 100 mg of Ang-(1-7), did not significantly
change the thrombus weight in SHRs. In addition, we
evaluated whether chronic treatment with this formula-
tion could result in desensitization of the antithrombotic
Figure 2 - The antithrombotic effect of Ang-(1-7)-CyD is dependent on Mas. A) Ang-(1-7)-CyD promoted a reduction in FeCl3 solution-
induced thrombus weight in Mas+/+ mice; this effect was absent in Mas-/- mice. B) Oral administration of Ang-(1-7)-CyD [equivalent of
100 mg of Ang-(1-7)] increases the plasma level of Ang-(1-7) in C57Bl/6 mice. *p,0.05 and **p,0.01 significantly different from the
control group treated with CyD (unpaired Student’s t-test). Each column represents the mean ¡ SEM from 6-8 experiments.
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effect. Strikingly, prolonged oral treatment with Ang-(1-
7)-CyD promoted a potent antithrombotic effect in SHRs
(67% inhibition of thrombus formation, 4.27¡ 1.03 mg vs.
1.39 mg ¡ 0.68 mg, n = 10 and n = 7, respectively) (Figure
1B). No difference was observed between the treatments
with CyD alone, water or Ang-(1-7) alone (data not
shown).
The antithrombotic effect of Ang-(1-7)-CyD is
dependent on Mas
Based on the antithrombotic effect of Ang-(1-7)-CyD
observed in SHRs, we next evaluated the role of the Mas
receptor on this activity using a Mas-knocked out mouse.
The oral formulation Ang-(1-7)-CyD [equivalent of 100 mg of
Ang-(1-7)] inhibited thrombus formation in Mas+/+ mice.
However, this effect was abolished in Mas-/- mice (Mas+/+:
0.76 ¡ 0.10 mg vs. 0.37 ¡ 0.02 mg, n = 6 and n = 7,
respectively; Mas-/-: 0.97¡ 0.11 mg vs. 0.87¡ 0.14 mg; n = 6
and n = 6, respectively, Figure 2A). No difference was
observed among groups treated with CyD, water or Ang-
(1-7) in Mas+/+ mice (data not shown).
Ang-(1-7)-CyD promotes an increase in the plasma
level of Ang-(1-7)
We then verified whether oral treatment with Ang-(1-7)-
CyD could increase the plasma level of Ang-(1-7). Using wild
type mice, we observed that this formulation promoted a
significant increase in the plasma level of Ang-(1-7) (7.79¡
0.40 pg/mL vs. 19.52 ¡ 7.38 pg/mL, n = 8 and n = 6,
respectively) (Figure 2B). Treatment with vehicles did not
promote any change in the plasma level of Ang-(1-7) (water:
7.73¡ 0.70 pg/mL; CyD: 7.79¡ 0.40 pg/mL; Ang-(1-7): 7.80
¡ 1.14 pg/mL).
DISCUSSION
This is the first study to demonstrate the biological
activity of the oral formulation Ang-(1-7)-CyD. Further-
more, we observed that the potent antithrombotic activity of
this formulation is dependent on Mas and involves an
increase in the plasma level of Ang-(1-7).
Recently, significant efforts have been made to identify
new drug treatments for thrombogenic diseases because
thrombogenic events remain a major cause of morbidity and
mortality worldwide.2 Ang-(1-7) is a peptide that promotes
many beneficial cardiovascular effects, counter-regulating
many of the actions induced by Ang II.6,7 Its effects include
vasodilation,18,19 improvements in post-ischemic contractile
function,20,21 antifibrotic activity,22 improvements in
endothelial function23,24 and antithrombotic activity.10,14 All
of these effects suggest that Ang-(1-7) is a potential target for
treating cardiovascular disease.
In the present study, we showed that oral administration
of Ang-(1-7)-CyD promotes an antithrombotic effect that
was associated with an increase in the plasma concentra-
tion of Ang-(1-7). Furthermore, the antithrombotic effect of
Ang-(1-7)-CyD was abolished in Mas-/- mice. We recently
demonstrated that Mas is present on platelets and that the
interaction between Ang-(1-7) and Mas on platelets
stimulates the production of NO,12 which is the major
antiplatelet agent. Moreover, Ang-(1-7), via Mas, promotes
NO and prostacyclin24 production from endothelial cells,
which are important antithrombotic agents in the
hemostatic process.25,26 Thus, the antithrombotic effect of
Ang-(1-7) may be due to its interaction with Mas in both
platelets and endothelial cells.12 Together, these findings
suggest that the antithrombotic effect of Ang-(1-7)-CyD is
due to the increase in plasma Ang-(1-7) levels and
consequent activation of Mas on platelets and endothelial
cells.
Acute treatment with Ang-(1-7)-CyD, in doses equivalent
to 10 or 30 mg/kg of Ang-(1-7), promoted a potent
antithrombotic effect in SHRs. On the other hand, a higher
dose of Ang-(1-7)-CyD [equivalent to 100 mg/kg of Ang-(1-
7)] did not significantly inhibit thrombus formation. This
finding is in accordance with previous studies showing a
bell-shaped dose-response curve for this heptapeptide. For
instance, using an intravenous infusion of Ang-(1-7),
Kucharewicz et al.10 observed that the antithrombotic effect
of Ang-(1-7) was abolished at higher doses. We observed the
same phenomenon when evaluating the antithrombotic
effect of Ang-(1-7) in mice.12 We evaluated whether chronic
treatment with this formulation could produce desensitiza-
tion of the antithrombotic effect. No evidence for that was
obtained; instead, daily treatment with Ang-(1-7)-CyD over
the course of eight weeks produced an even greater
antithrombotic effect than that of acute treatment in SHR
(60% and 67% thrombus weight inhibition for acute and
prolonged treatment, respectively).
Inclusion compounds such as Ang-(1-7)-CyD are com-
monly used by the pharmaceutical industry because they
promote the enhancement of drug stability, absorption
across biological barriers and gastric protection against
digestive enzyme degradation.14 The formulation based on
the inclusion complex formed between Ang-(1-7) and CyD
was developed to allow oral administration of Ang-(1-7)
and was recently characterized by Lula et al.,15 although its
biological action had not been evaluated previously. We
have shown that Ang-(1-7)-CyD can increase the plasma
level of Ang-(1-7) when administered orally (Figure 2B), and
its action is dependent on Mas (Figure 2A). However, the
exact mechanism leading to the Ang-(1-7)-CyD-induced
increase in plasma Ang-(1-7) levels is unknown. One
hypothesis is that the inclusion compound is not degraded
until it reaches the colon and that the colon microflora break
CyD into small saccharides, delivering the peptide, which
could then be absorbed.15
In summary, our study shows that oral administration of
Ang-(1-7)-CyD produces a clear antithrombotic effect, and
this effect can be explained by an increase in the plasma
level of Ang-(1-7) and consequent activation of Mas.
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